Pfizer Reports Booster Shots 95.6% Effective, Offer "Favorable" Safety Profile_老虎社区_美港股上老虎

Pfizer Reports Booster Shots 95.6% Effective, Offer "Favorable" Safety Profile

zerohedge2021-10-21

Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the "science" later, Pfizer and BioNTech on Thursday released ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Ken81
·2021-10-21
ok
回复
1
举报
收起
- Ken81:
  Ok
  2021-10-21
  回复
  举报
Ferocious
·2021-10-21
Ok
回复
1
举报
收起
- Decaffed:
  Ok
  2021-10-21
  回复
  举报
- Ferocious:
  Ok
  2021-10-21
  回复
  举报
HermioneG
·2021-10-21
Awesome!
回复
1
举报
收起
- JASRICH:
  K
  2021-10-21
  回复
  举报
- mistyzenz:
  mm
  2021-10-21
  回复
  举报
Tanyl
·2021-10-21
PFE price start to up yesterday
回复
4
举报
Linnleo
·2021-10-21
Hmm.. wondering wat is the side effects
回复
4
举报
收起
- Linnleo:
  gd news though
  2021-10-21
  回复
  举报
- Sim1:
  Dunno
  2021-10-21
  回复
  举报
S土豪熊貓G
·2021-10-21
Not cutting corners?
回复
5
举报
收起
- S土豪熊貓G:
  Ok
  2021-10-21
  回复
  举报
- S土豪熊貓G:
  Ok
  2021-10-21
  回复
  举报
- 滚股怪:
  Like
  2021-10-21
  回复
  举报
查看更多 1 条评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-21 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145207572","market":"us","top_or_hot":-1,"title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile","media":"zerohedge","content":"<div>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released ...\n\n<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile>zerohedge</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released ...\n\n<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","article_id":"1145207572","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","pubTimestamp":1634819824,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","collect":0,"end_time":0,"defaultTopTitle":"zerohedge.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞报告强化注射95.6%有效，提供“有利”的安全配置","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":853530752,"gmtCreate":1634823283688,"gmtModify":1634823283924,"author":{"id":"3585213688830112","authorId":"3585213688830112","name":"Ken81","avatar":"https://static.tigerbbs.com/418cd48b74e205c2447c77f326f1817c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585213688830112","idStr":"3585213688830112"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853530752","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6277498,"gmtCreate":1634823291655,"gmtModify":1634823291751,"authorId":3585213688830112,"author":{"id":3585213688830112,"idStr":"3585213688830112","authorId":3585213688830112,"name":"Ken81","avatar":"https://static.tigerbbs.com/418cd48b74e205c2447c77f326f1817c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853530752,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":853597084,"gmtCreate":1634823197792,"gmtModify":1634823198082,"author":{"id":"3586857174644620","authorId":"3586857174644620","name":"Ferocious","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3586857174644620","idStr":"3586857174644620"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853597084","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6277478,"gmtCreate":1634823225839,"gmtModify":1634823225875,"authorId":3579499629384357,"author":{"id":3579499629384357,"idStr":"3579499629384357","authorId":3579499629384357,"name":"Decaffed","avatar":"https://static.tigerbbs.com/233f0ca062b0a4857cce119c33bc9a64","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853597084,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6277469,"gmtCreate":1634823203166,"gmtModify":1634823203273,"authorId":3586857174644620,"author":{"id":3586857174644620,"idStr":"3586857174644620","authorId":3586857174644620,"name":"Ferocious","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853597084,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":853599926,"gmtCreate":1634822469310,"gmtModify":1634822574387,"author":{"id":"3581581151725380","authorId":"3581581151725380","name":"HermioneG","avatar":"https://static.tigerbbs.com/449ae31dcb8cfcd4dcedab9bc5dec8aa","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581581151725380","idStr":"3581581151725380"},"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853599926","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6277426,"gmtCreate":1634822910910,"gmtModify":1634822911024,"authorId":3574948385311046,"author":{"id":3574948385311046,"idStr":"3574948385311046","authorId":3574948385311046,"name":"JASRICH","avatar":"https://static.tigerbbs.com/f7ba205e3b289d35d298ed9ecc1aca5f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853599926,"type":1,"supId":6277405,"prevId":0,"content":"K","text":"K","html":"K"},{"id":6277405,"gmtCreate":1634822840651,"gmtModify":1634822840762,"authorId":3561962801944040,"author":{"id":3561962801944040,"idStr":"3561962801944040","authorId":3561962801944040,"name":"mistyzenz","avatar":"https://static.tigerbbs.com/b6ce5e71746857498b3364479f136e14","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853599926,"type":1,"supId":0,"prevId":0,"content":"mm","text":"mm","html":"mm"}],"langContent":"CN"},{"id":853503394,"gmtCreate":1634821399194,"gmtModify":1634821399603,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4087109808120260","idStr":"4087109808120260"},"htmlText":"PFE price start to up yesterday","listText":"PFE price start to up yesterday","text":"PFE price start to up yesterday","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853503394","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":853272360,"gmtCreate":1634820837922,"gmtModify":1634820838286,"author":{"id":"3584658134750205","authorId":"3584658134750205","name":"Linnleo","avatar":"https://static.tigerbbs.com/b57e83af12c17b31db1fb1b80ea44c6a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3584658134750205","idStr":"3584658134750205"},"htmlText":"Hmm.. wondering wat is the side effects","listText":"Hmm.. wondering wat is the side effects","text":"Hmm.. wondering wat is the side effects","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853272360","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6277002,"gmtCreate":1634820898906,"gmtModify":1634824960182,"authorId":3584658134750205,"author":{"id":3584658134750205,"idStr":"3584658134750205","authorId":3584658134750205,"name":"Linnleo","avatar":"https://static.tigerbbs.com/b57e83af12c17b31db1fb1b80ea44c6a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853272360,"type":1,"supId":0,"prevId":0,"content":"gd news though","text":"gd news though","html":"gd news though"},{"id":6277048,"gmtCreate":1634821190785,"gmtModify":1634821190829,"authorId":3573709257975993,"author":{"id":3573709257975993,"idStr":"3573709257975993","authorId":3573709257975993,"name":"Sim1","avatar":"https://static.tigerbbs.com/45f90a5e23b6dc713a314a1c2365d6b6","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853272360,"type":1,"supId":0,"prevId":0,"content":"Dunno","text":"Dunno","html":"Dunno"}],"langContent":"CN"},{"id":853271186,"gmtCreate":1634820520723,"gmtModify":1634820541797,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":9,"crmLevelSwitch":0,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"htmlText":"Not cutting corners?&nbsp;","listText":"Not cutting corners?&nbsp;","text":"Not cutting corners?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/853271186","repostId":1145207572,"repostType":4,"repost":{"id":"1145207572","kind":"news","pubTimestamp":1634819824,"share":"https://www.laohu8.com/m/news/1145207572?lang=zh_CN&edition=full","pubTime":"2021-10-21 20:37","market":"us","language":"en","title":"Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145207572","media":"zerohedge","summary":"Offering Americans the latest reminder that the dynamic driving our national vaccine program priorit","content":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Reports Booster Shots 95.6% Effective, Offer \"Favorable\" Safety Profile<blockquote>辉瑞报告加强注射有效率为95.6%，提供“有利”的安全性</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nzerohedge2021-10-21 20:37\n\n</h4>\n</header>\n<article>\nOffering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).<blockquote>辉瑞和BioNTech周四发布了一项3期试验的疗效数据，旨在表明他们的加强剂量恢复了对新冠肺炎的疗效，比最初的2疗程剂量（最初被认为约为91%的有效性）提供了更多的保护，这向美国人提供了最新的提醒，即推动我们国家疫苗计划的动力首先优先考虑政策决定，然后是“科学”。</blockquote> Additionally, the data showed the booster jabs had a \"favorable safety profile\".<blockquote>此外，数据显示加强注射具有“良好的安全性”。</blockquote> The datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.<blockquote>该数据发布在《新英格兰医学杂志》上，该杂志用这张图表按年龄组说明了增强剂的疗效。</blockquote> <img src=\"https://static.tigerbbs.com/59aaae9fd3ce49d4d177a57a1db0df20\" tg-width=\"1280\" tg-height=\"1392\" width=\"100%\" height=\"auto\">The latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.<blockquote>最新数据显示，在Delta毒株流行期间，接种第三剂疫苗的16岁或以上参与者对疾病的有效性为95.6%。此外，研究还发现加强注射具有良好的安全性。</blockquote> Here's more from Reuters:<blockquote>以下是路透社的更多内容：</blockquote> Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses. The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement. The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. Pfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.<blockquote>辉瑞曾表示，其两针疫苗的有效性会随着时间的推移而下降，并引用了一项研究，该研究显示，在第二剂疫苗接种四个月后，有效性从96%的峰值降至84%。一些国家已经开始实施加强剂量的计划。制药商表示，研究中第二剂与加强注射或安慰剂之间的中位时间约为11个月，并补充说，加强组中只有5例COVID-19病例，而接受安慰剂注射的组中有109例。辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“这些结果进一步证明了加强剂的好处，因为我们的目标是让人们免受这种疾病的侵害。”参与者的中位年龄为53岁，55.5%的参与者年龄在16至55岁之间，23.3%的参与者年龄在65岁或以上。辉瑞首席执行官Albert Bourla在一份声明中庆祝了这一数据，宣称它清楚地表明加强剂量可以恢复对新冠病毒的全面保护，甚至是对德尔塔变异毒株病毒的保护。</blockquote> \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer&nbsp;Albert Bourla&nbsp;said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere. Back in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.<blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)在一份声明中表示：“我们相信，加强剂在应对这一流行病持续的公共卫生威胁方面可以发挥关键作用。”这些公司表示，他们将与美国、欧洲和其他地方的卫生当局分享这些数据。早在9月份，FDA和CDC就批准辉瑞疫苗开始用作最脆弱人群（老年人和免疫功能低下者）的加强注射，从而加快了监管审查进程，因为辉瑞仍在通过试验进行数据测试并通过测量免疫保护的下降来衡量对加强剂的需求。</blockquote> And just last night,the FDA gave the same EUA approval to the Moderna and J&amp;J jabs.<blockquote>就在昨晚，FDA对Moderna和J&amp;J疫苗给予了同样的EUA批准。</blockquote> The timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.<blockquote>这一数据出现的时机并非偶然。它是在一次重要的疾病预防控制中心会议之前向公众发布的，预计该机构将再次批准拜登政府推出加强剂的计划——不是针对辉瑞，而是针对Moderna和JNJ疫苗（辉瑞加强剂已经获得了FDA的EUA（紧急批准），疾病预防控制中心也在配合。尽管如此，拜登政府正在尽一切努力鼓励所有40岁以上的美国人准备在未来几个月接种加强针，如果他们还没有接种的话。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile\">zerohedge</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/covid-19/pfizer-reports-booster-shots-956-effective-offer-favorable-safety-profile","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145207572","content_text":"Offering Americans the latest reminder that the dynamic driving our national vaccine program prioritizesthe policy decisions first, and the \"science\" later, Pfizer and BioNTech on Thursday released efficacy data from a Phase 3 trial purported to show that their booster doses restore efficacy against COVID-19, offering even more protection than the original 2-course dose (which was originally believed to be around 91% effective).\nAdditionally, the data showed the booster jabs had a \"favorable safety profile\".\nThe datawas released to the New England Journal of Medicine, which illustrated the efficacy of the boosters by age group with this chart.\nThe latest data showed participants aged 16 or older who had been given a third dose showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. Additionally, the study also found that the booster shot had a favourable safety profile.\nHere's more from Reuters:\n\n Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.\n\n\n The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot.\n\n\n \"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,\" Pfizer CEO Albert Bourla said in a statement.\n\n\n The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.\n\nPfizer CEO Albert Bourla celebrated the data in a statement, proclaiming that it clearly shows booster doses restore full protection against COVID, even against the delta variant.\n\n \"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,\" Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.\n\nBack in September,both the FDA and CDC gave the Pfizer jabthe green light to start being used as booster shots for the most vulnerable - the elderly and the immunocompromised - expediting the process of regulatory review as Pfizer was still conducting data via trials to try and gauge the need for boosters by measuring the decline in immunity protection.\nAnd just last night,the FDA gave the same EUA approval to the Moderna and J&J jabs.\nThe timing of this data is no accident.It's being released to the public ahead of an important CDC meeting where the agency is expected to once again rubber stamp the Biden Administration's plans for rolling out boosters - not for Pfizer, but for the Moderna and JNJ jabs (Pfizer boosters have already received an EUA (emergency approval) from the FDA, with the CDC going along with it. Still, the Biden Administration is doing everything it can to encourage all Americans over 40 to prepare to get a booster jab in the coming months, if they haven't gotten one already.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6278407,"gmtCreate":1634827606506,"gmtModify":1634827606542,"authorId":3578811676095048,"author":{"id":3578811676095048,"idStr":"3578811676095048","authorId":3578811676095048,"name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853271186,"type":1,"supId":6277090,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6278403,"gmtCreate":1634827600342,"gmtModify":1634827600588,"authorId":3578811676095048,"author":{"id":3578811676095048,"idStr":"3578811676095048","authorId":3578811676095048,"name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853271186,"type":1,"supId":6277576,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6277576,"gmtCreate":1634823638148,"gmtModify":1634823638183,"authorId":4091089381144950,"author":{"id":4091089381144950,"idStr":"4091089381144950","authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853271186,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":6277090,"gmtCreate":1634821414463,"gmtModify":1634821414498,"authorId":4087650159745720,"author":{"id":4087650159745720,"idStr":"4087650159745720","authorId":4087650159745720,"name":"TerranceMike","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":853271186,"type":1,"supId":0,"prevId":0,"content":"Please like, thank you","text":"Please like, thank you","html":"Please like, thank you"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":26,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}